Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
Oridonin, an active diterpenoid isolated from Rabdosia rubescens, has been widely used for treatment of various types of cancer. It has been shown that oridonin produced an antiproliferative effect in a lung cancer cell line in vitro. However, the antitumor effects of oridonin in lung cancer cells xenograft mice were poorly understood. The aim of the current study was to investigate the antitumor activity of oridonin in vivo and the molecular mechanisms mediating this antitumor efficacy. The human A549 and NCI-H292 non-small cell lung cancer cell lines were transferred to nude mice for the establishment of xenograft models. The results showed that oridonin (10, 20, 40 mg/kg, intraperitoneally) treatment for 28 days significantly decreased tumor volume and induced tumor growth inhibition in both A549 and NCI-H292 xenograft mice. Furthermore, oridonin promoted apoptosis by increasing terminal dUTP nick end labeling-positive cells as well as the ratio of Bax/Bcl-2 in xenograft mice. In addition, chronic oridonin administration inhibited mammalian target of rapamycin (mTORC1) activity by reduction of p-mTOR and p-p70s6k levels, suggesting that the increased apoptosis triggered by oridonin administration was associated with the downregulation of mTORC1 activity. Moreover, inhibition of mTORC1 by rapamycin (2 mg/kg, intraperitoneally) enhanced the anticancer activity of oridonin in mice xenograft models. These findings indicate that treatment with oridonin exhibited antitumor actions through induction of apoptotic response by inhibition of mTORC1 function. Our results also proposed the potential that inhibition of mTORC1 might be an effective target for increasing the therapeutic outcome in lung cancer patients treated with oridonin.